Overview
Using Implementation Science to Improve Multidisciplinary Diagnostic and Treatment Pathways for Patients With PAH
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
• Integrate evidence-based approaches in the screening and diagnosis of PAH
• Implement treatment algorithms and clinical trial evidence in practice to optimize initial treatment selection and ongoing treatment modifications in PAH
• Establish MDT roles and workflows for monitoring therapy, facilitating access, and providing whole-person care for patients with PAH
Diagnostic Standards
• Clinical classification
• Diagnostic criteria and testing
• Investigational markers and novel imaging modalities
PAH Risk Assessment and Treatment Algorithms
• Risk assessment to inform treatment strategies
- Treatment goals, escalation of treatment according to ongoing risk assessment
• Treatment guidelines
- Use of upfront combination therapy
• Latest clinical evidence
- Available therapies (MOAs, dosing/administration, safety and efficacy)
- Application of latest clinical and real-world evidence
• Challenges in treatment of PAH
Developing an Action Plan: Practical Strategies for Multidisciplinary Clinical Teams
• Establishing diagnostic and treatment protocols
• Expediting access to treatment
• Patient management
• Multidisciplinary team strategies
Professor of Medicine
Director, Cardiology Fellowship
Chief, General Cardiology
University of Utah
Salt Lake City, UT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Grants/Research Support: Acceleron/Merck, OrphAI, Pulmivant, Tectonics, United Therapeutics
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: imatinib, seralutinib, CS1, MK5475, dehydroepiandrosterone, and cibotercept are not approved for the treatment of PAH.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.5 contact hour.
ACPE Universal Activity Number: 0396-0000-25-005-H01-P
Activity Type: Application
Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit. CPE credit will be submitted to CPE Monitor® on the first business day of each month.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
